Disclosure Of Entity's Operating Segments [Text Block]

Xbrane Biopharma - Filing #679209

Concept	2023-01-01 to 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31
Disclosure of entity's operating segments [text block]	—	—	—	—	—	—
Disclosure of operating segments [text block]	—	—	—	—	—	—
Disclosure of operating segments [abstract]
Disclosure of operating segments [line items]
Revenue	238 729 SEK	—	—	—	57 618 SEK	—
Tax expense (income)	– SEK	—	—	—	– SEK	—
Profit (loss) before tax	322 028 SEK	—	—	—	168 513 SEK	—
Profit (loss) from continuing operations	322 028 SEK	—	—	—	168 513 SEK	—
Profit (loss)	388 172 SEK	—	388 172 SEK	—	172 513 SEK	172 513 SEK
Assets	—	653 508 SEK	—	690 515 SEK	—	—
Liabilities	—	482 173 SEK	—	265 626 SEK	—	—
Cash flows from (used in) operating activities	406 678 SEK	—	—	—	193 918 SEK	—
Cash flows from (used in) investing activities	16 769 SEK	—	—	—	60 125 SEK	—
Cash flows from (used in) financing activities	298 696 SEK	—	—	—	148 864 SEK	—
Disclosure of products and services [text block]	—	—	—	—	—	—
Disclosure of products and services [abstract]
Disclosure of products and services [line items]
Disclosure of geographical areas [text block]	—	—	—	—	—	—
Disclosure of geographical areas [abstract]
Disclosure of geographical areas [line items]
Disclosure of major customers [text block]	—	—	—	—	—	—
Disclosure of major customers [abstract]
Disclosure of major customers [line items]